A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer
| Autor: | Caroline Domerg, Ming-Sound Tsao, Frances A. Shepherd, Stephen L. Graziano, Sinead Cuffe, Elizabeth Laureen Strevel, Monia Ezzalfani, Pasi A. Jänne, Marzia Capelletti, Lesley Seymour, Ronald Burkes, Abderrahmane Bourredjem, Jean-Pierre Pignon |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Male Lung Neoplasms medicine.medical_treatment DNA Mutational Analysis Platinum Compounds 030204 cardiovascular system & hematology medicine.disease_cause 0302 clinical medicine Carcinoma Non-Small-Cell Lung Medicine Aged 80 and over Hazard ratio DNA Neoplasm Middle Aged Prognosis 3. Good health Survival Rate Leukemia Chemotherapy Adjuvant 030220 oncology & carcinogenesis Female KRAS Pulmonary and Respiratory Medicine Adult KRAS mutations medicine.medical_specialty TNM staging Disease-Free Survival Article Proto-Oncogene Proteins p21(ras) 03 medical and health sciences Internal medicine Proto-Oncogene Proteins Carcinoma Biomarkers Tumor Humans Lung cancer Survival rate Aged Neoplasm Staging Retrospective Studies Chemotherapy business.industry Non–small-cell lung cancer Cancer Tumor size medicine.disease United States Adjuvant chemotherapy Mutation ras Proteins business Follow-Up Studies |
| Zdroj: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 7(6) |
| ISSN: | 1556-1380 |
| Popis: | Introduction The staging of node-negative non–small-cell lung cancer is modified in the 7th edition TNM classification. Here, we pool data from the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial and the Cancer and Leukemia Group B-9633 trial to explore the prognostic and predictive effects of the new T-size descriptors and KRAS mutation status. Methods Node-negative patients were reclassified as T2a (>3–⩽5 cm), T2b (>5–⩽7 cm), T3 (>7 cm) or T ⩽ 3 cm (⩽3 cm, but other T2 characteristics). Results Of 538 eligible patients, 288 (53.5%) were T2a, 111 (21%) T2b, 62 (11.5%) T3, whereas 77 (14%) T⩽3 cm were excluded to avoid confounding. KRAS mutations were detected in 104 of 390 patients (27%). T-size was prognostic for disease-free survival ( p = 0.03), but borderline for overall survival (OS; p = 0.10), on multivariable analysis. Significant interaction between the prognostic value of KRAS and tumor size was observed for OS ( p = 0.01), but not disease-free survival ( p = 0.10). There was a nonsignificant trend ( p = 0.24) for increased chemotherapy effect on OS with advancing T-size (hazard ratio [HR] T2a 0.90, [0.63–1.30]; T2b 0.69, [0.38–1.24]; and T3 0.57, [0.28–1.17]). The HR for chemotherapy effect on OS in T2a patients with KRAS wild-type tumors was 0.81 ( p = 0.36), whereas a trend for detrimental effect was observed in those with mutant tumors (HR 2.11; p = 0.09; interaction p = 0.05). Similar trends were observed in T2b to T3 patients with wild-type (HR 0.86; p = 0.62), and KRAS mutant tumors (HR 1.16; p = 0.74; interaction p = 0.58). Conclusion Chemotherapy effect seems to increase with tumor size. However, this small study could not identify subgroups of patients who did or did not derive significant benefit from adjuvant chemotherapy based on T-size or KRAS status. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|